# The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell Lymphoma

> **NCT02679196** · PHASE1 · COMPLETED · sponsor: **Karus Therapeutics Limited** · enrollment: 23 (actual)

## Conditions studied

- Lymphoma, B Cell

## Interventions

- **DRUG:** KA2237

## Key facts

- **NCT ID:** NCT02679196
- **Lead sponsor:** Karus Therapeutics Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07
- **Primary completion:** 2018-12-24
- **Final completion:** 2018-12-24
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2019-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02679196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02679196, "The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02679196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*